Haemonetics reports Q4 adjusted EPS $1.24, consensus $1.22

Reports Q4 revenue $330.6M, consensus $329.38M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “We delivered solid earnings growth in our fiscal 2025, with record margin expansion and strong cash flow as evidence of the health and vitality of our businesses. Our industry-leading NexSys, TEG and VASCADE technologies continue to propel our growth in attractive markets, and we are on track to deliver all of the goals of our four-year long-range plan in fiscal 2026.”